TRCT
TSHA icon

Tower Research Capital (TRC)’s Taysha Gene Therapies TSHA Stock Holding History

Tower Research Capital (TRC)’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78.5K Sell
11,530
-14,554
-56% -$86.1K ﹤0.01% 2371
2026
Q1 		$117K Buy
26,084
+25,609
+5,391% +$119K ﹤0.01% 2062
2025
Q4 		$2.61K Sell
475
-6,132
-93% -$29.8K ﹤0.01% 4495
2025
Q3 		$21.6K Sell
6,607
-10,999
-62% -$31.1K ﹤0.01% 3246
2025
Q2 		$40.7K Buy
17,606
+10,742
+156% +$23.3K ﹤0.01% 3142
2025
Q1 		$9.54K Sell
6,864
-44,221
-87% -$74K ﹤0.01% 3762
2024
Q4 		$88.4K Buy
51,085
+37,233
+269% +$77.2K ﹤0.01% 2210
2024
Q3 		$27.8K Buy
13,852
+815
+6% +$1.79K ﹤0.01% 3049
2024
Q2 		$29.2K Sell
13,037
-11,092
-46% -$32.3K ﹤0.01% 3504
2024
Q1 		$69.3K Buy
24,129
+21,258
+740% +$44.3K ﹤0.01% 2061
2023
Q4 		$5.08K Buy
+2,871
New +$5.72K ﹤0.01% 4883
2023
Q3 		– Sell
-14,435
Closed -$9.54K – 6240
2023
Q2 		$9.54K Buy
14,435
+7,180
+99% +$5.2K ﹤0.01% 4260
2023
Q1 		$6K Sell
7,255
-3,763
-34% -$4.86K ﹤0.01% 4885
2022
Q4 		$25K Buy
11,018
+1,655
+18% +$3.35K ﹤0.01% 2932
2022
Q3 		$18K Buy
9,363
+6,104
+187% +$22.2K ﹤0.01% 4028
2022
Q2 		$12K Buy
3,259
+1,659
+104% +$6.58K ﹤0.01% 4314
2022
Q1 		$10K Buy
1,600
+420
+36% +$3.14K ﹤0.01% 4352
2021
Q4 		$14K Buy
1,180
+390
+49% +$5.88K ﹤0.01% 4109
2021
Q3 		$15K Sell
790
-186
-19% -$3.54K ﹤0.01% 4000
2021
Q2 		$21K Buy
976
+350
+56% +$8.07K ﹤0.01% 3857
2021
Q1 		$13K Buy
626
+333
+114% +$9.02K ﹤0.01% 4226
2020
Q4 		$8K Buy
+293
New +$6.31K ﹤0.01% 4441

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tower Research Capital (TRC)'s TSHA Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Taysha Gene Therapies (TSHA) stake by 56% in Q2 2026, selling an estimated $86.1K and leaving 11,530 shares worth $78.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2371.

Tower Research Capital (TRC) first reported a position in TSHA in Q4 2020 and has held it in 22 quarters since. The position peaked at $117K in Q1 2026. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Tower Research Capital (TRC) held 11,530 shares of Taysha Gene Therapies worth $78.5K as of Q2 2026.
  • Tower Research Capital (TRC) sold 14,554 Taysha Gene Therapies shares in Q2 2026, an estimated $86.1K.
  • Taysha Gene Therapies made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2371 holding.
  • Tower Research Capital (TRC) first reported a position in Taysha Gene Therapies in Q4 2020 and has held it in 22 quarters since.
  • Tower Research Capital (TRC)'s Taysha Gene Therapies position peaked at $117K in Q1 2026.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.